Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 76 (3), 258-269

Antibody Persistence and Booster Responses 24-36 Months After Different 4CMenB Vaccination Schedules in Infants and Children: A Randomised Trial

Affiliations
Clinical Trial

Antibody Persistence and Booster Responses 24-36 Months After Different 4CMenB Vaccination Schedules in Infants and Children: A Randomised Trial

Federico Martinón-Torres et al. J Infect.

Abstract

Objectives: This phase IIIb, open-label, multicentre, extension study (NCT01894919) evaluated long-term antibody persistence and booster responses in participants who received a reduced 2 + 1 or licensed 3 + 1 meningococcal serogroup B vaccine (4CMenB)-schedule (infants), or 2-dose catch-up schedule (2-10-year-olds) in parent study NCT01339923.

Materials and methods: Children aged 35 months to 12 years (N = 851) were enrolled. Follow-on participants (N = 646) were randomised 2:1 to vaccination and non-vaccination subsets; vaccination subsets received an additional 4CMenB dose. Newly enrolled vaccine-naïve participants (N = 205) received 2 catch-up doses, 1 month apart (accelerated schedule). Antibody levels were determined using human serum bactericidal assay (hSBA) against MenB indicator strains for fHbp, NadA, PorA and NHBA. Safety was also evaluated.

Results: Antibody levels declined across follow-on groups at 24-36 months versus 1 month post-vaccination. Antibody persistence and booster responses were similar between infants receiving the reduced or licensed 4CMenB-schedule. An additional dose in follow-on participants induced higher hSBA titres than a first dose in vaccine-naïve children. Two catch-up doses in vaccine-naïve participants induced robust antibody responses. No safety concerns were identified.

Conclusion: Antibody persistence, booster responses, and safety profiles were similar with either 2 + 1 or 3 + 1 vaccination schedules. The accelerated schedule in vaccine-naïve children induced robust antibody responses.

Keywords: 2 + 1 schedule; Antibody persistence; Booster response; Children; Infants; Meningococcal B vaccine; Open-label randomised clinical trial; Safety.

Similar articles

See all similar articles

Cited by 3 articles

Publication types

Associated data

LinkOut - more resources

Feedback